Pacira Pharmaceuticals Inc. (PCRX)

31.20
0.65 2.10
NASDAQ : Health Technology
Prev Close 30.55
Open 30.90
Day Low/High 30.30 / 31.35
52 Wk Low/High 29.35 / 58.95
Volume 604.62K
Avg Volume 837.30K
Exchange NASDAQ
Shares Outstanding 40.57M
Market Cap 1.22B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals

First Week Of PCRX August 2018 Options Trading

First Week Of PCRX August 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Expanded roles reflect key accomplishments and demonstrated leadership

Interesting PCRX Put And Call Options For January 2018

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair

First Week of PCRX May 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 637,865 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 5,288,719, an increase of 13.72% since 08/15/2017.

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,627,603 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 4,650,854, an increase of 53.84% since 07/31/2017.

TheStreet Quant Rating: D (Sell)